During the past decade, Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 10 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "German CLL Study Group" with 3 trials sponsored, "Arrowhead Pharmaceuticals" with 2 trials sponsored, "Astellas Pharma Inc" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II" #1 collaborator was "Basilea Pharmaceutica International Ltd" with 2 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Array BioPharma" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II" are "Leukemia" (3 trials), "Multiple Myeloma" (3 trials), "Myelodysplastic Syndromes" (3 trials), "Aspergillosis" (2 trials) and "Chronic Lymphocytic Leukemia" (2 trials). Many other conditions were trialed in "Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II" are "Drug" (25 trials), "Biological" (2 trials), "Other" (2 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (3 trials), "Rituximab" (3 trials), "Fludarabine" (2 trials), "Placebo" (2 trials) and "antihistamine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II" are 29 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".